share_log
Moomoo 24/7 ·  Mar 4 07:05
C4 Therapeutics Has Entered Into A License Agreement With Merck KGaA, To Exclusively Discover Two Targeted Protein Degraders Against Critical Oncogenic Proteins, C4 Therapeutics Will Receive $16M As Upfront And Is Eligible Of Up $740M In Milestone Payment
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment